US 12,403,181 B2
Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
David Klatzmann, Paris (FR); Jérémie Mariau, Fontenay-sous-Bois (FR); Paul-Gydéon Ritvo, Paris (FR); Encarnita Mariotti-Ferrandiz, Paris (FR); Thomas Vazquez, Montreuil (FR); and Nicolas Billiald, Paris (FR)
Assigned to ILTOO PHARMA, Paris (FR); SORBONNE UNIVERSITE, Paris (FR); ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS, Paris (FR); INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA, Paris (FR); and RECHERCHE MÉDICALE), Paris (FR)
Appl. No. 17/268,030
Filed by ILTOO PHARMA, Paris (FR); SORBONNE UNIVERSITE, Paris (FR); ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS, Paris (FR); and INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), Paris (FR)
PCT Filed Aug. 13, 2019, PCT No. PCT/EP2019/071684
§ 371(c)(1), (2) Date Feb. 11, 2021,
PCT Pub. No. WO2020/035482, PCT Pub. Date Feb. 20, 2020.
Claims priority of application No. 18306112 (EP), filed on Aug. 13, 2018.
Prior Publication US 2021/0236599 A1, Aug. 5, 2021
Int. Cl. A61K 38/20 (2006.01); A61K 38/17 (2006.01); A61K 47/62 (2017.01); C07K 16/24 (2006.01)
CPC A61K 38/2013 (2013.01) [A61K 38/177 (2013.01); A61K 47/62 (2017.08); C07K 16/245 (2013.01)] 17 Claims
 
1. A method for increasing regulatory T cells and reducing inflammation in a subject in need thereof, the method comprising administering to the subject a combination of i) interleukin-2 (IL-2) and ii) an interleukin 1 (IL-1) inhibitor, wherein the IL-1 inhibitor is a recombinant IL-1Rα.